You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Programmed Cell Death Receptor Ligand 2 (PDL2, PD-L2)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +4 more
  • MK-2870
  • +2 more
  • (no location specified)
Sep 15, 2023

Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Chuo-ku, Tokyo, Japan
    National Cancer Center Hospital ( Site 3700)
Jan 31, 2023

HLA-A2 Positive Cells Present, Refractory Melanoma Trial in Buffalo (Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1

Recruiting
  • HLA-A2 Positive Cells Present
  • Refractory Melanoma
  • Alpha-type-1 Polarized Dendritic Cells
  • +5 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Dec 12, 2022

Urothelial Carcinoma Trial in Worldwide (Zilovertamab vedotin)

Recruiting
  • Urothelial Carcinoma
  • Zilovertamab vedotin
  • Cleveland, Ohio
  • +11 more
Jan 25, 2023

Lung Cancer, Non-Small Cell Trial in Worldwide (Pembrolizumab, Dostarlimab, GSK4428859A)

Recruiting
  • Lung Cancer, Non-Small Cell
  • Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
  • +14 more
Dec 26, 2022

Advanced Melanoma Trial in Worldwide (lenvatinib, pembrolizumab)

Active, not recruiting
  • Advanced Melanoma
  • Chandler, Arizona
  • +22 more
Jul 21, 2022

Cervical Carcinoma, Chemoradiotherapy, Anti-programmed Cell Death Receptor 1 Trial in Beijing (Camrelizumab plus Concurrent

Recruiting
  • Cervical Carcinoma
  • +8 more
  • Camrelizumab plus Concurrent chemoradiotherapy
  • Beijing, Beijing, China
    Lei Li
Apr 5, 2022

Germ Cell Tumor Trial in Milano (Durvalumab, Tremelimumab)

Terminated
  • Germ Cell Tumor
  • Milano, Italy
    Fondazione IRCCS Istituto Nazionale dei Tumori
May 12, 2021

NSCLC Trial in China (Pembrolizumab, Lenvatinib, Placebo for lenvatinib)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • Pembrolizumab
  • +2 more
  • Hefei, Anhui, China
  • +16 more
Oct 14, 2022

Non Small Cell Lung Cancer, Solid Tumor Trial in Fairfax (BBP-398 with nivolumab)

Recruiting
  • Non Small Cell Lung Cancer
  • Solid Tumor
  • BBP-398 with nivolumab
  • Springdale, Arkansas
  • +6 more
Jan 27, 2023

Metastatic Solid Tumors, NSCLC, Melanoma Trial in United States (INBRX-105 - PDL1x41BB antibody, Pembrolizumab)

Recruiting
  • Metastatic Solid Tumors
  • +7 more
  • Scottsdale, Arizona
  • +12 more
Jan 26, 2023

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Tumor Trial in

Suspended
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
May 23, 2022

Tumors Trial in United States (Niraparib, Pembrolizumab, TSR-042 (Dostarlimab))

Completed
Has Results
  • Neoplasms
  • Whittier, Alaska
  • +15 more
Aug 29, 2022

Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer Trial in Seattle (Aldesleukin,

Recruiting
  • Advanced Clear Cell Renal Cell Carcinoma
  • +3 more
  • Aldesleukin
  • Pembrolizumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 5, 2022

Hepatitis B, Chronic Trial in Worldwide (JNJ-73763989, PD-1 inhibitor, Tenofovir Disoproxil)

Recruiting
  • Hepatitis B, Chronic
  • Vancouver, British Columbia, Canada
  • +31 more
Jan 17, 2023

Breast Tumors Trial in Israel, Korea, Republic of, United States (Atezolizumab (MPDL3280A), an engineered anti-programmed

Active, not recruiting
  • Breast Neoplasms
  • Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody
  • +7 more
  • Birmingham, Alabama
  • +26 more
Dec 21, 2022

Tumor-Infiltrating Lymphocytes and Programmed Cell Death -

Recruiting
  • Breast Cancer
  • +2 more
  • Observational Study
  • Lucknow, Uttar Pradesh, India
    Sanjay Gandhi Postgraduate Institute of Medical Sciences
Feb 11, 2022

Metastatic Non Small Cell Lung Cancer Trial in Worldwide (Pembrolizumab/Vibostolimab coformuation, Docetaxel, Placebo)

Active, not recruiting
  • Metastatic Non Small Cell Lung Cancer
  • Pembrolizumab/Vibostolimab coformuation
  • +2 more
  • Los Angeles, California
  • +94 more
Jan 4, 2023

Small Cell Lung Carcinoma Trial in Worldwide (coformulation pembrolizumab/quavonlimab, lenvatinib, MK-4830)

Active, not recruiting
  • Small Cell Lung Carcinoma
  • coformulation pembrolizumab/quavonlimab
  • +3 more
  • Gilbert, Arizona
  • +46 more
Jan 2, 2023

Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer Trial (favezelimab/pembrolizumab, pembrolizumab, lenvatinib)

Not yet recruiting
  • Solid Tumor
  • +2 more
  • favezelimab/pembrolizumab
  • +2 more
  • (no location specified)
Sep 7, 2023

Oral Cancer, VEGFR2 Inhibitor, Programmed Cell Death 1 Inhibitor Trial in Shanghai (drug, procedure, radiation)

Active, not recruiting
  • Oral Cancer
  • +3 more
  • Shanghai, Shanghai, China
    Shanghai Ninth People's Hospital
Jul 23, 2021

NSCLC Trial in Worldwide (Sacituzumab Govitecan-hziy (SG), Docetaxel)

Recruiting
  • Non-Small Cell Lung Cancer
  • Anchorage, Alaska
  • +104 more
Jul 20, 2022

Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma, Persistent Cervical Carcinoma Trial in Beijing (Tislelizumab plus

Recruiting
  • Recurrent Cervical Carcinoma
  • +9 more
  • Tislelizumab plus radiotherapy
  • Beijing, Beijing, China
    Lei Li
Apr 1, 2022

Urothelial Carcinoma, Triple Negative Breast Cancer, NSCLC Trial (SBT6290, pembrolizumab)

Withdrawn
  • Urothelial Carcinoma
  • +4 more
  • (no location specified)
Apr 4, 2022

Melanoma Trial in Worldwide (Pembrolizumab, Quavonlimab, Vibostolimab)

Recruiting
  • Melanoma
  • Pembrolizumab
  • +4 more
  • Los Angeles, California
  • +34 more
Jan 25, 2023